202 related articles for article (PubMed ID: 2479714)
1. Serological prospects for peptide vaccines against foot-and-mouth disease virus.
Parry NR; Ouldridge EJ; Barnett PV; Clarke BE; Francis MJ; Fox JD; Rowlands DJ; Brown F
J Gen Virol; 1989 Nov; 70 ( Pt 11)():2919-30. PubMed ID: 2479714
[TBL] [Abstract][Full Text] [Related]
2. Immunization against foot-and-mouth disease with synthetic peptides representing the C-terminal region of VP1.
Doel TR; Gale C; Brooke G; DiMarchi R
J Gen Virol; 1988 Sep; 69 ( Pt 9)():2403-6. PubMed ID: 2457649
[TBL] [Abstract][Full Text] [Related]
3. Mimicry of viral epitopes with retro-inverso peptides of increased stability.
Benkirane N; Guichard G; Briand JP; Muller S; Brown F; Van Regenmortel MH
Dev Biol Stand; 1996; 87():283-91. PubMed ID: 8854029
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immunogenicity and cross-reactivity of retro-inverso peptidomimetics of the major antigenic site of foot-and-mouth disease virus.
Muller S; Guichard G; Benkirane N; Brown F; Van Regenmortel MH; Briand JP
Pept Res; 1995; 8(3):138-44. PubMed ID: 7670228
[TBL] [Abstract][Full Text] [Related]
5. A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot-and-mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence.
Barnett PV; Pullen L; Staple RF; Lee LJ; Butcher R; Parkinson D; Doel TR
J Gen Virol; 1996 May; 77 ( Pt 5)():1011-8. PubMed ID: 8609466
[TBL] [Abstract][Full Text] [Related]
6. Progress and perspectives in the development of a foot-and-mouth disease vaccine by recombinant DNA technology.
Brown F
Prog Vet Microbiol Immunol; 1987; 3():59-72. PubMed ID: 2483918
[No Abstract] [Full Text] [Related]
7. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate.
Mayr GA; Chinsangaram J; Grubman MJ
Virology; 1999 Oct; 263(2):496-506. PubMed ID: 10544121
[TBL] [Abstract][Full Text] [Related]
8. [Neutralization of foot-and-mouth disease virus O1 Campos by antibodies induced by a synthetic peptide].
Piccone M; Zuloaga G; Marcovecchio F; Arese A; Monesiglio JC; Palma EL
Rev Argent Microbiol; 1988; 20(2):69-75. PubMed ID: 2845477
[TBL] [Abstract][Full Text] [Related]
9. Protection conferred by TrpE fusion proteins containing portions of the C-terminal region of capsid protein VP1 of foot-and-mouth disease virus.
Giavedoni LD; Kaplan G; Marcovecchio F; Piccone ME; Palma EL
J Gen Virol; 1991 Apr; 72 ( Pt 4)():967-71. PubMed ID: 1849980
[TBL] [Abstract][Full Text] [Related]
10. Bovine herpesvirus-1 (infectious bovine rhinotracheitis virus)-based viral vector which expresses foot-and-mouth disease epitopes.
Kit M; Kit S; Little SP; Di Marchi RD; Gale C
Vaccine; 1991 Aug; 9(8):564-72. PubMed ID: 1722936
[TBL] [Abstract][Full Text] [Related]
11. Qualitative and quantitative differences in the immune response to foot-and-mouth disease virus antigens and synthetic peptides.
Francis MJ; Fry CM; Rowlands DJ; Brown F
J Gen Virol; 1988 Oct; 69 ( Pt 10)():2483-91. PubMed ID: 2844964
[TBL] [Abstract][Full Text] [Related]
12. Multiple variants in foot-and-mouse disease virus (FMDV) populations: the Achilles heel for peptide and rec. DNA vaccines?
Barteling SJ; Woortmeyer R
Dev Biol Stand; 1987; 66():511-21. PubMed ID: 3034708
[TBL] [Abstract][Full Text] [Related]
13. Comparison between in vitro neutralization titres and in vivo protection against homologous and heterologous challenge induced by vaccines prepared from two serologically distinct variants of foot-and-mouth disease virus, serotype A22.
Bolwell C; Parry NR; Rowlands DJ
J Gen Virol; 1992 Mar; 73 ( Pt 3)():727-31. PubMed ID: 1312129
[TBL] [Abstract][Full Text] [Related]
14. Recognition of B and T cell epitopes by cattle immunized with a synthetic peptide containing the major immunogenic site of VP1 FMDV 01 Campos.
Zamorano P; Wigdorovitz A; Chaher MT; Fernandez FM; Carrillo C; Marcovecchio FE; Sadir AM; Borca MV
Virology; 1994 Jun; 201(2):383-7. PubMed ID: 8184548
[TBL] [Abstract][Full Text] [Related]
15. The potential of retro-inverso peptides as synthetic vaccines.
Van Regenmortel MH; Guichard G; Benkirane N; Briand JP; Muller S; Brown F
Dev Biol Stand; 1998; 92():139-43. PubMed ID: 9554267
[TBL] [Abstract][Full Text] [Related]
16. Modified-live infectious bovine rhinotracheitis virus vaccine expressing monomer and dimer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles.
Kit S; Kit M; DiMarchi RD; Little SP; Gale C
Arch Virol; 1991; 120(1-2):1-17. PubMed ID: 1718244
[TBL] [Abstract][Full Text] [Related]
17. Protection against viral infections with the aid of synthetic peptides. Foot-and-mouth disease as an example.
Vol'pina OM; Surovoi AYu ; Ivanov VT
Biomed Sci; 1990 Jan; 1(1):23-32. PubMed ID: 1718462
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.
Parry NR; Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F
J Gen Virol; 1989 Jun; 70 ( Pt 6)():1493-503. PubMed ID: 2471812
[TBL] [Abstract][Full Text] [Related]
19. Conformational preferences of a peptide corresponding to the major antigenic determinant of foot-and-mouth disease virus: implications for peptide-vaccine approaches.
de Prat-Gay G
Arch Biochem Biophys; 1997 May; 341(2):360-9. PubMed ID: 9169027
[TBL] [Abstract][Full Text] [Related]
20. Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif.
Brown F; Benkirane N; Limal D; Halimi H; Newman JF; Van Regenmortel MH; Briand JP; Muller S
Vaccine; 1999 Aug; 18(1-2):50-6. PubMed ID: 10501234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
